AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Welcome and introduction
Date
14 Sep 2020Session
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinomaPresenters
Ghassan Abou-AlfaAuthors
G.K. Abou-AlfaAuthor affiliations
- Medicine Department, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, 10065 - New York/US
Resources
Resources from the same session
Brief overview of immuno-oncology in HCC
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations in first-line advanced HCC: Current evidence and ongoing trials
Presenter: Peter Galle
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
IO combinations early or intermediate-stage HCC: Current evidence and ongoing trials
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Putting it all together: Case discussions
Presenter: Bruno Sangro
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
Summary, final thoughts, and audience question and answer session
Presenter: Ghassan Abou-Alfa
Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.